Keros Therapeutics
KROS
KROS
123 hedge funds and large institutions have $901M invested in Keros Therapeutics in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 60 increasing their positions, 27 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
5% less funds holding
Funds holding: 129 → 123 (-6)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Holders
123
Holding in Top 10
3
Calls
$518K
Puts
$20K
Top Buyers
| 1 | +$46M | |
| 2 | +$11.3M | |
| 3 | +$5.79M | |
| 4 |
CA
CHI Advisors
New York
|
+$5.67M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.45M |
Top Sellers
| 1 | -$39.7M | |
| 2 | -$9.87M | |
| 3 | -$7.12M | |
| 4 |
Citigroup
New York
|
-$6.96M |
| 5 |
O
OrbiMed
New York
|
-$6.62M |